Icon

NARCAN (nda016636)- (0.02MG/ML,0.4MG/ML,1MG/ML)

NALOXONE HYDROCHLORIDE ADAPT
0.02MG/ML,0.4MG/ML,1MG/ML
No No
Expired Expired
None None
None No
NARCAN is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. NARCAN is also indicated for diagnosis of suspected or known acute opioid overdosage.
24 0 22
Total Other Developers None
Drugs with Suitability No
0.02MG/ML ** ** - - -
0.4MG/ML ** ** - - 6
1MG/ML ** ** - - 4
NDA Sales Available Total Generic Sales Available
No 18
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* *******, ***. *********** **** ***** ********** *****, *********, ****** (**) *****, ****** ****** (***) ***
****** ******* *******, ***. *********** ******* *** *****, ***** *****, ***** ******** (**) *****, ****** ****** (***) ***
****** ******* *******, ***. *********** ******* *** *****, ***** *****, ***** ******** (**) *****, ****** ****** (***) ***
****** ***** ***** *************** *** ***. *********** * ********** ****, ****** ****, *** ****** (**) *****, ****** ****** (***) ***
****** ***** ************* ***** ******** *********** *******, ** ******, , ******* (***) ***
****** ***** ************* ***** ******** *********** *******, ** ******, , ******* (***) ***
****** ******** ******* *** ******** ************ ******* ******* *********** **/*, ******** ******* *********** *****, *********, ********* ******, ***** (***) ***
****** ******** ******* *** ******** ************ ******* ******* *********** **/*, ******** ******* *********** *****, *********, ********* ******, ***** (***) ***
****** ****** ***** ********* ******* *** (*** *****) *********** **** **** ***** ***., *******, ******** (**) *****, ****** ****** (***) ***
****** ****** ***** ********* ******* *** (*** *****) *********** **** **** ***** ***., *******, ******** (**) *****, ****** ****** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ****** ******** **** *** ****** ***. *********** **. **, ******* *. **., *****, ******* ******, ****** (***) ***
****** ****** ******** **** *** ****** ***. *********** **. **, ******* *. **., *****, ******* ******, ****** (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***
****** ********* **** *** ********* **** ***, *** *********** **** ********* ******* ****, ******, ***** ******** (**) *****, ****** ****** (***) ***
****** **** ********** ************* ********** *******, ***. *********** **** ***** ***** ***., ***** ** *****, ********** (**) *****, ****** ****** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ****** ******** ********* *** *********** ***** * *******, ******, *****, ****** (***) ***
****** ***** **** *** ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** **** ********** *** ******* ******** *** *********** *** ******** **., *********, ******** (**) *****, ****** ****** (***) ***
****** *** **** *** **** *** *********** ***** * ******* ** *** ***, *****, ******* (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.